MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49: 12-19.
Häuser W, Finn DP, Kalso E, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain. 2018;22(9): 1547-1564.
Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4): 327-360.
Bouquié R, Deslandes G, Mazaré H, et al. Cannabis and anticancer drugs: societal usage and expected pharmacological interactions – a review. Fundam Clin Pharmacol. 2018;32(5): 462-484.
Health Canada. Information for Health Care Professionals: Cannabis (marihuana, marijuana) and the cannabinoids. Health Canada; 2018.
Sativex Oromucosal Spray, Summary of Product Characteristics. Medicines and Healthcare Products Regulatory Agency. Approved 21-05-2020. Accessed on 25-09-2020
Nielsen S, Sabioni P, Trigo JM, et al. Opioid-sparing effect of cannabinoids: a systematic review and meta-analysis. Neuropsychopharmacology. 2017;42: 1752–1765.
Lucas P, Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. Int J Drug Policy. 2017;42: 30-35.
Lucas P, Baron EP, Jikomes N. Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients. Harm Reduct J. 2019;16(1): 9.
Baron EP, Lucas P, Eades J, Hogue O. Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. J Headache Pain. 2018;19(1): 37.
ADAC. Drogen im Straßenverkehr. www.adac.de/verkehr/verkehrssicherheit/verkehrsmedizin/drogen-im-strassenverkehr. Accessed October 1, 2021.